Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Digital health tools

Topic: Amyloid, tau and blood-test diagnosis

Dementia and mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) are neurological pathologies associated with disruptions in brain electromagnetic activity, typically studied using magnetoencephalography (MEG) and electroencephalography (EEG). To quantify diverse brain properties, different families of parameters can be computed from MEG and EEG (i.e., spectral, non-linear, morphological, functional connectivity, or network structure and organisation). However, studying these characteristics separately overlooks the complex nature of brain activity. Integrative frameworks can be useful to unveil the intricate neurophysiological fingerprint, as well as to characterise pathological conditions comprehensively. To that purpose, data fusion methodologies are crucial, despite their interpretational challenges. In this study, Machine Learning (ML) models were trained to discriminate between groups of severity, whereas the SHapley Additive eXplanations (SHAP) algorithm was afterwards utilised to assess the relevance of the input characteristics into the output classification. Three databases were analysed: MEG (55 healthy controls, HC, 42 MCI patients, and 86 AD patients), EEG1 (51 HC, 52 MCI, and 100 AD), and EEG2 (45 HC, 69 MCI, and 82 AD). The best results for the three-class classification problem were obtained by Gradient Boosting for the MEG database: 3-class Cohen’s kappa coefficient of 0.5452 and accuracy of 72.63 %. Afterwards, using SHAP on Gradient Boosting, it has been shown that spectral features were identified as highly relevant across all databases. Furthermore, morphology measures presented high relevance for the MEG database, whereas EEG1 and EEG2 databases showed functional connectivity and multiplex organisation measures, respectively, as relevant subgroups of parameters. Finally, commonly relevant features across databases were selected using SHAP to generate the neurophysiological fingerprints of AD and MCI. This study highlights the relevance of different MEG and EEG parameters in characterising neurological pathologies. The proposed framework, based on MEG and EEG, can be used to generate interpretable, robust, and accurate neurophysiological fingerprints of AD and MCI.

Key findings

Why it matters

This study trained machine learning models on brain electromagnetic data from MEG and EEG to tell apart healthy controls, people with mild cognitive impairment and people with Alzheimer's disease, with the best result reaching about 72.63% accuracy. It is a diagnostic classification study and does not test any treatment, cure or prevention.

Study details

How this study scored 38/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 1 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomised / blinded 0 of 2; Times cited 2 of 7; Citations per year 2 of 5; Impact for its field and year 3 of 6; Cited by studies here 0 of 6; Still being cited 1 of 4; Senior author's track record 2 of 4; Institution's track record 0 of 3; Multi-centre collaboration 2 of 3; Indexed in PubMed 1 of 2; Free to read 2 of 2. Total 38 of 100.38 of 100 points earned62 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Journal of Applied Biomedicine)
Journal's citation record 1 / 4 Journal of Applied Biomedicine: journal h-index 81 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomised / blinded 0 / 2 No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 2 / 7 Cited 11 times (OpenAlex, 2026-10-10)
Citations per year 2 / 5 3.7 citations a year over 3 year(s) since 2025
Impact for its field and year 3 / 6 Cited 7.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 1 / 4 Cited 11 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Carlos Gómez: h-index 32 (OpenAlex, whole career)
Institution's track record 0 / 3 Centro de Investigación Biomédica en Red: institution h-index 530 (OpenAlex)
Multi-centre collaboration 2 / 3 OpenAlex lists 5 institution(s) in 2 countries
Indexed in PubMed 1 / 2 Not in PubMed, but has a DOI
Free to read 2 / 2 Free to read
Total 38 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

APA 7th

Pablo, V. G.-d., Herrero-Tudela, M., Sandonís-Fernández, M., Poza, J., Maturana-Candelas, A., Rodríguez-González, V., et al. (2025). Integrative and interpretable framework to unveil the neurophysiological fingerprint of Alzheimer’s disease and mild cognitive impairment: A machine learning-SHAP approach. Journal of Applied Biomedicine. https://doi.org/10.1016/j.bbe.2025.05.011

Vancouver

Pablo VG.-d, Herrero-Tudela M, Sandonís-Fernández M, Poza J, Maturana-Candelas A, Rodríguez-González V, et al. Integrative and interpretable framework to unveil the neurophysiological fingerprint of Alzheimer’s disease and mild cognitive impairment: A machine learning-SHAP approach. Journal of Applied Biomedicine. 2025. doi:10.1016/j.bbe.2025.05.011.

BibTeX

@article{pablo2025-0d3ba250,
  author  = {Pablo, Víctor Gutiérrez-de and Herrero-Tudela, María and Sandonís-Fernández, Marina and Poza, Jesús and Maturana-Candelas, Aarón and Rodríguez-González, Víctor and Tola-Arribas, Miguel Ángel and Cano, Mónica and others},
  title   = {{Integrative and interpretable framework to unveil the neurophysiological fingerprint of Alzheimer’s disease and mild cognitive impairment: A machine learning-SHAP approach}},
  journal = {Journal of Applied Biomedicine},
  year    = {2025},
  doi     = {10.1016/j.bbe.2025.05.011},
  url     = {https://doi.org/10.1016/j.bbe.2025.05.011}
}

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Digital health tools

Similar studies

More on Digital health tools

See all studies in Digital health tools →